Double-Masked, Placebo-Controlled Study of Intravenous Levetiracetam for the Treatment of Status Epilepticus and Acute Repetitive Seizures in Dogs

被引:55
|
作者
Hardy, B. T.
Patterson, E. E.
Cloyd, J. M.
Hardy, R. M.
Leppik, I. E. [1 ,2 ]
机构
[1] Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA
[2] MINCEP Epilepsy Care, Minneapolis, MN USA
关键词
Canine; Cluster seizures; Epilepsy; Pharmacokinetics; ANTIEPILEPTIC DRUG LEVETIRACETAM; CONVULSIVE STATUS EPILEPTICUS; CANINE STATUS EPILEPTICUS; IDIOPATHIC EPILEPSY; PHARMACOKINETICS; MANAGEMENT; PHENYTOIN; LORAZEPAM; DIAZEPAM; PROFILE;
D O I
10.1111/j.1939-1676.2011.00868.x
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Background: Status epilepticus (SE) and acute repetitive seizures (ARS) are common canine neurologic emergencies. No evidence-based studies are available to guide treatment in veterinary patients. Parenteral levetiracetam (LEV) has many favorable properties for the emergency treatment of seizures, but its safety and efficacy in dogs for SE and ARS are unknown. Hypothesis: Intravenous LEV is superior to placebo in controlling seizures in dogs with SE or ARS after treatment with IV diazepam. Animals: Nineteen client-owned dogs admitted for SE or ARS. Methods: Randomized, placebo-controlled, double-masked study. Dogs with SE or ARS were randomized to receive IV LEV (30 or 60 mg/kg using an adaptive dose-escalation approach) or placebo, in addition to standard of care treatment. They were monitored for at least 24 hours after admission for additional seizures. Results: The responder rate (defined as dogs with no additional seizures after administration of the study medication) after LEV was 56% compared with 10% for placebo (P = .06). Dogs in the placebo group required significantly more boluses of diazepam compared with the LEV group (P < .03). Seizure etiologies identified were idiopathic epilepsy (n = 10), inflammatory central nervous system disease (n = 4), intracranial neoplasia (n = 2), hepatic encephalopathy (n = 1), and 2 dogs had no cause determined. No serious adverse effects were attributable to LEV administration. Conclusions and Clinical Importance: LEV was safe and potentially effective for the treatment of SE and ARS in these client-owned dogs. Larger, controlled clinical trials are needed to confirm this preliminary observation.
引用
收藏
页码:334 / 340
页数:7
相关论文
共 50 条
  • [41] High-dose intravenous methylprednisolone in recent traumatic optic neuropathy; a randomized double-masked placebo-controlled clinical trial
    Morteza Entezari
    Zhaleh Rajavi
    Neda Sedighi
    Narssis Daftarian
    Masoumeh Sanagoo
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2007, 245 : 1267 - 1271
  • [42] Clinical course and radiographic resolution of pneumonia in dogs treated with a shorter versus longer course of antimicrobials: a randomized, double-masked, placebo-controlled study
    Reineke, Erica L.
    Mcclosky, Megan E.
    Mauro, Katie D.
    Schlax, Adam
    Mcgonigle, Kathryn M.
    Scavello, Heather
    Cole, Stephen D.
    Redding, Laurel E.
    JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 2025, 263 (01): : 47 - 53
  • [43] High-dose intravenous methylprednisolone in recent traumatic optic neuropathy; a randomized double-masked placebo-controlled clinical trial
    Entezari, Morteza
    Rajavi, Zhaleh
    Sedighi, Neda
    Daftarian, Narssis
    Sanagoo, Masoumeh
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2007, 245 (09) : 1267 - 1271
  • [44] Drops for Presbyopia: Results of CSF-1, a multicenter randomized double-masked placebo-controlled crossover study
    Socea, Sergiu
    Mimouni, Michael
    Andreja, Veselica
    Blumenthal, Eytan Z.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [45] A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis
    Dell, SJ
    Lowry, GM
    Northcutt, JA
    Howes, J
    Novack, GD
    Hart, K
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 102 (02) : 251 - 255
  • [46] Levetiracetam intravenous infusion: A randomized, placebo-controlled safety and pharmacokinetic study
    Ramael, Steven
    Daoust, Agnes
    Otoul, Christian
    Toublanc, Nathalie
    Troenaru, Mona
    Lu, Zhihong
    Stockis, Armel
    EPILEPSIA, 2006, 47 (07) : 1128 - 1135
  • [47] Levetiracetam intravenous infusion: A randomised placebo-controlled safety study.
    Ramael, S
    Troenaru, M
    Toublanc, N
    Daoust, A
    Otoul, C
    Lu, Z
    Stockis, A
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P81 - P81
  • [48] MDLSD: study protocol for a randomised, double-masked, placebo-controlled trial of repeated microdoses of LSD in healthy volunteers
    Robin J. Murphy
    Rachael L. Sumner
    William Evans
    David Menkes
    Ingo Lambrecht
    Rhys Ponton
    Frederick Sundram
    Nicholas Hoeh
    Sanya Ram
    Lisa Reynolds
    Suresh Muthukumaraswamy
    Trials, 22
  • [49] The effects of Rimexolone 1% in postoperative inflammation after cataract extraction. A double-masked placebo-controlled study
    Bron, A
    Denis, P
    Hoang-Xuan, TC
    Boureau-Andrieux, C
    Crozafon, P
    Hachet, E
    Medhorn, E
    Akingbehin, A
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 1998, 8 (01) : 16 - 21
  • [50] Intravitreal ranibizumab for persistent diabetic vitreous haemorrhage: a randomised, double-masked, placebo-controlled feasibility study.
    Petrarca, Robert
    Soare, Cristina
    Wong, Roger
    Desai, Riti
    Neffendorf, James
    Simpson, Andrew
    Jackson, Timothy L.
    ACTA OPHTHALMOLOGICA, 2020, 98 (08) : E960 - E967